Effect of decitabine on serum platelet derived growth factor levels in patients with leukemia
10.3969/j.issn.1005-1678.2016.04.30
- VernacularTitle:地西他滨对白血病患者血清血小板衍生生长因子水平的影响
- Author:
Xuefen YAN
;
Jinghan WANG
;
Fenzhi WU
;
Hongwei KONG
- Publication Type:Journal Article
- Keywords:
decitabine;
acute myeloid leukemia;
PDGF
- From:
Chinese Journal of Biochemical Pharmaceutics
2016;36(4):100-101,104
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of decitabine on serum platelet derived growth factor levels in patients with leukemia. Methods 120 cases of acute myeloid leukemia patients admitted to our hospital from January 2012 to December 2014 were selected as the study subjects.The control group was given CAG regimen: 1-14 d Seventh days of intravenous infusion of 20 mg/d aclarubicin, first to fourteen days subcutaneous injection of 10 mg/m2 , 1 times per 12 h, 1-13 d cytosine arabinosine days under the subcutaneous injection of granulocyte colony stimulating factor 300μg/d.The observation group was given to the west of the lake 25 mg/d, intravenous infusion, used for 5 days.The levels of platelet derived growth factor PDGF in the two groups were compared and the therapeutic effect.Results Before treatment, differences of PDGF in control group and observation group was no statistical significance.After treatment, PDGF in observation group was lower than control group ( P <0.05).The proportion of primary cells of bone marrow of two groups after treatment was lower than before treatment, and the observation group was more lower.Total effective rate of observation group was 55.0%,which was higher than that in control group(35.0%)(P<0.05).Conclusion Decitabine could reduce the level of of PDGF in patients with leukemia, and improve the total effective rate.
